Brucker BM, Jericevic D, Rude T, et al. - Researchers compared mirabegron vs solifenacin among multiple sclerosis patients with overactive bladder (OAB) symptoms, focusing on the patient-perceived effectiveness and tolerability of these agents. Prospective recruitment of patients who were not on medication for their urinary symptoms at enrollment was done. The alteration in OAB Questionnaire Short Form symptom severity and minimal clinically important difference (MCID) achievement was the primary outcome. During treatment span, bowel function was evaluated applying the Patient Assessment of Constipation Symptoms. Response rates to mirabegron and solifenacin in this patient sample were found to be similar, with nearly 50%-70% attaining each patient reported outcome measure's MCID. Although some short-term evidence was generated that solifenacin afforded greater improvement in urinary symptom severity, it is necessary to weigh this potential advantage against the evident risk of worsening constipation.